2025-05-14 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the data you provided. The report is structured to provide a clear overview of the company's performance, recent developments, and key financial metrics.

## RXRX Analysis: Recursion Pharmaceuticals Inc.

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

**Key Figures:**

*   **RXRX Cumulative Return:** -57.96%
*   **VOO Cumulative Return:** 14.68%
*   **Absolute Divergence (Last Day):** -72.6%
*   **Relative Divergence:** 0.0

**Analysis:**

RXRX has significantly underperformed the S&P 500 (VOO) over the period examined. The cumulative return difference of -72.6% indicates a substantial gap in performance. The Relative Divergence of 0.0 suggests that RXRX is at the lower end of its historical performance range relative to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
| ---------- | ------- | ------ | ------- | ------ | ------ |
| 2021-2023  | 5.0%    | 73.6%  | 1.0%    | -0.1   | 4.0    |
| 2022-2024  | 0.0%    | 73.6%  | -17.0%   | -0.1   | 2.8    |
| 2023-2025  | -6.0%   | 73.6%  | -36.0%   | -0.1   | 1.8    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) has declined over the periods presented, indicating weakening growth.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high (73.6%), highlighting significant risk and volatility.
*   **Alpha:** The negative Alpha values, particularly in recent periods, show that RXRX is significantly underperforming relative to its benchmark.
*   **Beta:** The negative Beta suggests a slight inverse correlation with the market, but the value is close to zero, indicating very little market sensitivity.
*   **Cap(B):** The declining capitalization size of the company in Billion US dollars, indicating market sell-off in general

### 2. Recent Price Action

**Key Figures:**

*   **Current Price:** $4.51
*   **Previous Close:** $4.64
*   **Change:** -2.8%
*   **5-day Moving Average:** $4.412
*   **20-day Moving Average:** $5.194
*   **60-day Moving Average:** $6.1061

**Analysis:**

The stock is currently trading below all three moving averages (5-day, 20-day, and 60-day), indicating a short-term and intermediate-term downtrend. The recent price decrease of -2.8% further supports this bearish trend.

### 3. Market Risk Indicators

**Key Figures:**

*   **Market Risk Indicator (MRI):** 0.3485 (Low Risk)
*   **RSI:** 32.85 (Oversold)
*   **PPO:** -1.44
*   **20-day Relative Divergence Change:** 0.0 (Negative trend)
*   **Expected Return:** -2429.1%

**Analysis:**

*   **MRI:** The MRI suggests low market risk, although this might not fully reflect the company-specific risks.
*   **RSI:** The RSI is in oversold territory, which could indicate a potential for a short-term bounce, but also suggests sustained selling pressure.
*   **PPO:** The negative PPO indicates that the short-term moving average is below the long-term moving average, confirming a downtrend.
*   **20-day Relative Divergence Change:** A negative change confirms the short-term underperformance relative to the benchmark.
*   **Expected Return:** The extremely negative expected return suggests significant potential downside risk and that RXRX will significantly underperform S&P 500 in the long term.
*   **Recent Volatility:** The price change of -2.8% from the previous close, suggests that the stock price is highly volatile.

### 4. Recent News & Significant Events

*   **May 13, 2025:** Major business developments, regulatory changes, or market events impacting RXRX.
*   **May 10, 2025:** Analyst discussions regarding recent performance and outlook, considering industry trends and global economic factors.
*   **May 11, 2025:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **May 12, 2025:** Market experts highlight both risks and opportunities, advising investors to monitor recent news.

**Analysis:**

Recent news indicates significant activity and volatility surrounding RXRX. Investors should closely monitor these developments for potential impacts on the stock's performance.

### 5. Recent Earnings Analysis

| 날짜       | EPS     | 매출        |
| ---------- | ------- | ----------- |
| 2025-05-05 | -0.5    | 0.01 B$     |
| 2024-11-06 | -0.34   | 0.03 B$     |
| 2024-08-08 | -0.4    | 0.01 B$     |
| 2024-05-09 | -0.39   | 0.01 B$     |
| 2025-05-05 | -0.39   | 0.01 B$     |

**Analysis:**

The data shows consistent negative EPS (Earnings Per Share) values, indicating a lack of profitability. Revenue has been variable, but generally low.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
| ------------ | -------- | ------------- |
| 2025-03-31   | $0.01B  | -47.31%       |
| 2024-12-31   | $0.00B  | -183.62%      |
| 2024-09-30   | $0.03B  | 53.69%        |
| 2024-06-30   | $0.01B  | 36.14%        |
| 2024-03-31   | $0.01B  | 17.23%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE       |
| ------------ | ------- | --------- |
| 2025-03-31   | $0.93B | -21.68%   |
| 2024-12-31   | $1.03B | -17.29%   |
| 2024-09-30   | $0.52B | -18.27%   |
| 2024-06-30   | $0.58B | -16.69%   |
| 2024-03-31   | $0.40B | -22.78%   |

**Analysis:**

*   **Revenue:** Revenue generation is inconsistent, with periods of low or zero revenue.
*   **Profit Margin:** Profit margins are volatile, with periods of high positive margins offset by significant losses.
*   **Equity:** Equity has fluctuated, indicating changes in the company's capital structure.
*   **ROE:** Negative Return on Equity (ROE) values indicate that the company is not generating profits relative to its equity.

### 7. 종합적 분석 (Overall Analysis)

RXRX is facing significant challenges. It has dramatically underperformed the S&P 500, exhibits high volatility and risk, and is currently in a downtrend. While the RSI suggests it is oversold, the negative alpha, consistent losses (negative EPS and ROE), and the extremely negative expected return indicate fundamental issues. Furthermore, the recent news events point to significant market activity and potential risks. Investors should exercise caution and closely monitor the company's developments.

**In Summary:** RXRX appears to be a high-risk investment with significant challenges to overcome.
